SCHEMBL160274

SCHEMBL160274

CCCCCCCCCCCCCCCCCCCOC=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.46
CA1 P00915 8/20 0.43
CA2 P00918 8/20 0.43
CA9 Q16790 7/20 0.43
LPAR3 Q9UBY5 3/20 0.43
CA12 O43570 3/20 0.43
CA7 P43166 3/20 0.43
CA14 Q9ULX7 3/20 0.43
LPAR1 Q92633 2/20 0.43
LPAR2 Q9HBW0 2/20 0.43
CA3 P07451 2/20 0.43
CA4 P22748 2/20 0.43
CA6 P23280 2/20 0.43
CA5A P35218 2/20 0.43
CA5B Q9Y2D0 2/20 0.43
NAAA Q02083 1/20 0.43
EPHX1 P07099 1/20 0.42
ADH1B P00325 1/20 0.42
ADH1C P00326 1/20 0.42
ADH1A P07327 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL154931 1.00 TSHR (0.46) TSHRCA1CA2CA9LPAR3
SCHEMBL2858734 1.00 TSHR (0.46) TSHRCA1CA2CA9LPAR3
SCHEMBL93202 1.00 TSHR (0.46) TSHRCA1CA2CA9LPAR3
SCHEMBL77313 1.00 TSHR (0.46) TSHRCA1CA2CA9LPAR3
SCHEMBL156980 1.00 TSHR (0.46) TSHRCA1CA2CA9LPAR3
SCHEMBL55804 1.00 TSHR (0.46) TSHRCA1CA2CA9LPAR3
SCHEMBL2857805 1.00 TSHR (0.46) TSHRCA1CA2CA9LPAR3
Hexyl Formate SCHEMBL59493 1.00
Heptyl Formate SCHEMBL93149 1.00 TSHR (0.46) TSHRCA1CA2CA9LPAR3
SCHEMBL2861030 1.00 TSHR (0.46) TSHRCA1CA2CA9LPAR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1142923-C 12, 13-modified epothilones derivatives ����˹�ж�-����˹˹������˾ 2004-03-24 CN claimed
CN-1298398-A 12,13-modified epothilone derivatives BRISTOL MYERS SQUIBB CO (US) 2001-06-06 CN claimed
CN-1285862-A Invert emulsion drilling fluid containing mixture of secondary esters obtained by conversion of olefins, and preparation thereof CHEVRON CHEMICAL CO PLC (US) 2001-02-28 CN claimed
CN-112512529-B Cyclopentenepurine derivative or salt thereof 富士胶片株式会社 2024-06-18 CN disclosed
EP-3831388-B1 CYCLOPENTENYL PURINE DERIVATIVE OR SALT THEREOF FOR USE IN SUPPRESSING ADENOVIRUS FUJIFILM CORP (JP) 2024-02-28 EP disclosed
CN-117434803-A Electrophotographic photoreceptor, process cartridge, and image forming apparatus 富士胶片商业创新有限公司 2024-01-23 CN disclosed
CN-117369230-A Electrophotographic photoreceptor, process cartridge, and image forming apparatus 富士胶片商业创新有限公司 2024-01-09 CN disclosed
US-20230295202-A1 CYCLOBUTYL PURINE DERIVATIVE OR SALT THEREOF FUJIFILM CORPORATION (JP) 2023-09-21 US disclosed
EP-3831836-B1 CYCLOBUTYL PURINE DERIVATIVE OR SALT THEREOF FUJIFILM CORP (JP) 2023-09-06 EP disclosed
CN-115956108-A Adhesive for endoscope, cured product thereof, endoscope, and method for producing endoscope 富士胶片株式会社 2023-04-11 CN disclosed
CN-107148423-B Thionucleoside derivative or salt thereof and pharmaceutical composition 富士胶片株式会社 2021-07-30 CN disclosed
WO-1995019959-A1 AMINO ACID DERIVATIVES AND THEIR USE AS PHOSPHOLIPASE A2 INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1995-07-27 WO disclosed
EP-0644199-A1 Cyclic antimicrobial peptides and preparation thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1995-03-22 EP disclosed
US-5376634-A Microbiocides FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1994-12-27 US disclosed
EP-0627406-A1 2-AMINO-1,3-PROPANEDIOL COMPOUND AND IMMUNOSUPPRESSANT YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 1994-12-07 EP disclosed
EP-0536936-A1 Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use Sankyo Company Limited (JP) 1993-04-14 EP disclosed
EP-0486011-A2 Pharmaceutical composition against Pneumocystis carinii FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1992-05-20 EP disclosed
EP-0462531-A2 Cyclic polypeptide with antibiotic activity, process for its preparation and pure culture of a Coelomycetes strain FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1991-12-27 EP disclosed
US-4433085-A Triazolidine-3,5-dione/formaldehyde/amine condensates and compositions thereof BAYER AKTIENGESELLSCHAFT (DE) 1984-02-21 US disclosed
EP-0044417-A2 Triazolidine-3,5-dione condensed with amine-formaldehyde, and its preparation BAYER AG (DE) 1982-01-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295202-A1 CYCLOBUTYL PURINE DERIVATIVE OR SALT THEREOF SLC28A1, SLC20A1, SLC29A1 TSHR 3730/4885CA1 1860/4885CA2 1567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.